FINWIRES · TerminalLIVE
FINWIRES

UiPath Posts Solid Fiscal Q2, Growth Re-acceleration Remains Limited, Oppenheimer Says

By

UiPath (PATH) delivered a solid fiscal Q2 but the results provided limited evidence of sustained growth re-acceleration, with the revenue beat driven mainly by professional services and licenses rather than subscriptions.

Management highlighted improving annual recurring revenue growth, execution and cost discipline, while guiding for fiscal Q3 ARR of about $1.99 billion to $2.00 billion and revenue of $440 million to $445 million, with adjusted operating income expected at $100 million.

Oppenheimer said the company also raised fiscal 2027 guidance, with ARR now expected at $2.065 billion to $2.07 billion; revenue at $1.789 billion to $1.794 billion, and adjusted operating income at $445 million.

The analysts highlighted Q2 net new ARR growth of 19% to $37 million and 109% net retention, but noted that subscription revenue missed consensus and Q3 guidance implied a 4% year-over-year decline in net new ARR at the midpoint.

Oppenheimer maintained its perform rating on the stock.

Shares of UiPath fell more than 13% in recent Friday trading.

Price: $15.72, Change: $-2.51, Percent Change: -13.75%

Related Articles

Wire

Vaxcyte Names New Medical and Legal Chiefs Ahead of Key Phase 3 Data

Vaxcyte (PCVX) appointed Luis Jodar as chief medical officer and David McAvoy as chief legal officer, the company said on Thursday.Jodar spent 17 years at Pfizer (PFE), most recently as senior vice president and chief medical officer for Vaccines and Infectious Diseases, the company said.McAvoy joins the company from Teva Pharmaceutical (TEVA), according to a statement.The vaccine developer also said it now expects to report topline data from its phase 3 OPUS-1 trial of VAX-31 in adults by the end of October, narrowing its previous guidance of a Q4 data release.

$PCVX
Wire

eGain Fiscal Q4 Adjusted Earnings, Revenue Fall; Shares Slump After Hours

EGain (EGAN) reported fiscal Q4 adjusted earnings late Thursday of $0.08 per diluted share, down from $0.09 a year earlier.Three analysts polled by FactSet projected $0.03.Revenue in the three months ended June 30 fell to $22.2 million from $23.2 million a year earlier.Three analysts projected $21.7 million.The company expects fiscal Q1 adjusted EPS of $0.05 to $0.08 on revenue of $20.9 million to $21.4 million. Three analysts project EPS of $0.08 on revenue of $22.3 million.For fiscal 2027, eGain expects adjusted EPS of $0.04 to $0.07 on revenue of $84.5 million to $86 million. Three analysts project EPS of $0.43 on revenue of $94.1 million.EGain shares slumped 29% in after-hours trading.

$EGAN
Wire

American Outdoor Brands Fiscal Q1 Swings to Adjusted Earnings, Revenue Rises

American Outdoor Brands (AOUT) reported fiscal Q1 non-GAAP earnings late Thursday of $0.03 per diluted share, swinging from a loss $0.26 year earlier.Two analysts polled by FactSet expected a loss of $0.24.Net sales for the quarter ended July 31 were $37.3 million, up from $29.7 million a year earlier.Two analysts expected $35.6 million.For fiscal 2027, the company maintained its net sales forecast of $200 million to $210 million. Two analysts expect $205.1 million.Shares of the company rose over 16% in after-hours trading.

$AOUT